Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin.
Kameda K, Kako S, Hayakawa J, Akahoshi Y, Komiya Y, Harada N, Ugai T, Ishihara Y, Kawamura K, Sakamoto K, Sato M, Kanda J, Tanihara A, Wada H, Terasako-Saito K, Kimura SI, Kikuchi M, Nakasone H, Kanda Y. Kameda K, et al. Among authors: kanda j, kanda y. Ann Hematol. 2018 Jan;97(1):169-179. doi: 10.1007/s00277-017-3141-4. Epub 2017 Sep 30. Ann Hematol. 2018. PMID: 28965134
Sustained molecular remission in a patient with CML in blastic crisis receiving dose-reduced hematopoietic stem-cell transplantation followed by early withdrawal of cyclosporine and prophylactic use of interferon-alpha.
Hamaki T, Kami M, Momomura S, Mineishi S, Kusumi E, Kanda Y, Ueyama J, Miyakoshi S, Morinaga S, Takaue Y, Mutou Y. Hamaki T, et al. Among authors: kanda y. Am J Hematol. 2002 Nov;71(3):196-9. doi: 10.1002/ajh.10203. Am J Hematol. 2002. PMID: 12410575 Free article.
Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution.
Nakai K, Mineishi S, Kami M, Saito T, Hori A, Kojima R, Imataki O, Hamaki T, Yoshihara S, Ohnishi M, Kim SW, Ando T, Fumitoh A, Kanda Y, Makimoto A, Tanosaki R, Kanai S, Heike Y, Ohnishi T, Kawano Y, Wakasugi H, Takaue Y. Nakai K, et al. Among authors: kanda y. Transplantation. 2003 Jun 27;75(12):2135-43. doi: 10.1097/01.TP.0000066453.32263.F7. Transplantation. 2003. PMID: 12829926
Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
Gondo H, Himeji D, Kamezaki K, Numata A, Tanimoto T, Takase K, Aoki K, Henzan H, Nagafuji K, Miyamoto T, Ishikawa F, Shimoda K, Inaba S, Tsukamoto H, Horiuchi T, Nakashima H, Otsuka T, Kato K, Kuroiwa M, Higuchi M, Shibuya T, Kamimura T, Kuzushima K, Tsurumi T, Kanda Y, Harada M. Gondo H, et al. Among authors: kanda y. Int J Hematol. 2004 Dec;80(5):441-8. doi: 10.1532/ijh97.04109. Int J Hematol. 2004. PMID: 15646657
Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies.
Oshima K, Kanda Y, Nakahara F, Shoda E, Suzuki T, Imai Y, Watanabe T, Asai T, Izutsu K, Ogawa S, Motokura T, Chiba S, Kurokawa M. Oshima K, et al. Among authors: kanda y. Am J Hematol. 2006 Nov;81(11):875-9. doi: 10.1002/ajh.20694. Am J Hematol. 2006. PMID: 16862551 Free article.
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y. Saito AM, et al. Among authors: kanda y. Am J Hematol. 2007 Oct;82(10):873-80. doi: 10.1002/ajh.20977. Am J Hematol. 2007. PMID: 17570513 Free article. Clinical Trial.
1,411 results